SCHEMBL6820122

SCHEMBL6820122

CCCCOc1ccc(CC(CC(=O)NO)S(=O)(=O)c2ccc(OC)cc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 15/20 0.74
MMP2 P08253 13/20 0.74
MMP3 P08254 12/20 0.74
PDE4A P27815 7/20 0.74
PDE4B Q07343 6/20 0.74
PDE4C Q08493 6/20 0.74
PDE4D Q08499 6/20 0.74
MMP9 P14780 2/20 0.55
MMP13 P45452 5/20 0.53
KDM4E B2RXH2 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2D6 P10635 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HIF1A Q16665 1/20 0.52
HDAC10 Q969S8 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
MMP7 P09237 3/20 0.52
MMP12 P39900 3/20 0.52
ACE P12821 2/20 0.52
ADAMTS4 O75173 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6824624 0.85 MMP2 (1.00) MMP1MMP2MMP3PDE4APDE4B
SCHEMBL6825866 0.85 MMP2 (0.85) MMP1MMP2MMP3PDE4APDE4B
SCHEMBL6823424 0.83 MMP1 (0.87) MMP1MMP2MMP3PDE4APDE4B
SCHEMBL6823613 0.83 MMP2 (0.87) MMP1MMP2MMP3PDE4APDE4B
SCHEMBL7064773 0.82 MMP1 (1.00) MMP1MMP2MMP3PDE4APDE4B
SCHEMBL5702920 0.79 PDE4A (0.77) MMP1MMP2MMP3PDE4APDE4B
SCHEMBL6825092 0.77 PDE4A (0.53) MMP1MMP2MMP3PDE4APDE4B
SCHEMBL7308283 0.75 MMP1 (0.80) MMP1MMP2MMP3PDE4APDE4B
SCHEMBL6824204 0.74 PDE4A (1.00) MMP1MMP2MMP3PDE4APDE4B
SCHEMBL6819965 0.74 PDE4A (1.00) MMP1MMP2MMP3PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6057369-A USE IN THE TREATMENT OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY WHICH ARE CAPABLE OF BEING MODULATED BY INHIBITING A MATRIX METALLOPROTEINASE (MMP), TUMOR NECROSIS FACTOR (TNF) OR CYCLIC AMP RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 2000-05-02 US claimed
EP-0871439-A4 SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS RHONE POULENC RORER PHARMA (US) 1999-07-21 EP claimed
EP-0871439-A1 SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1998-10-21 EP claimed
WO-1997024117-A1 SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-07-10 WO claimed
EP-0871439-B1 SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS AVENTIS PHARMA INC (US) 2004-03-31 EP disclosed
US-6057369-A USE IN THE TREATMENT OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY WHICH ARE CAPABLE OF BEING MODULATED BY INHIBITING A MATRIX METALLOPROTEINASE (MMP), TUMOR NECROSIS FACTOR (TNF) OR CYCLIC AMP RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 2000-05-02 US disclosed
EP-0871439-A4 SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS RHONE POULENC RORER PHARMA (US) 1999-07-21 EP disclosed
EP-0871439-A1 SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1998-10-21 EP disclosed
WO-1997024117-A1 SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-07-10 WO disclosed